477 related articles for article (PubMed ID: 26233890)
21. Dauricine inhibits viability and induces cell cycle arrest and apoptosis via inhibiting the PI3K/Akt signaling pathway in renal cell carcinoma cells.
Zhang S; Ren Y; Qiu J
Mol Med Rep; 2018 May; 17(5):7403-7408. PubMed ID: 29568902
[TBL] [Abstract][Full Text] [Related]
22. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
23. Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.
Zhu Q; Zhong AL; Hu H; Zhao JJ; Weng DS; Tang Y; Pan QZ; Zhou ZQ; Song MJ; Yang JY; He JY; Liu Y; Li M; Hu WM; Yang CP; Xiang T; Chen MY; Ma G; Guo L; Xia JC
J Hematol Oncol; 2020 Jan; 13(1):2. PubMed ID: 31900208
[TBL] [Abstract][Full Text] [Related]
24. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
25. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.
Kim J; Jonasch E; Alexander A; Short JD; Cai S; Wen S; Tsavachidou D; Tamboli P; Czerniak BA; Do KA; Wu KJ; Marlow LA; Wood CG; Copland JA; Walker CL
Clin Cancer Res; 2009 Jan; 15(1):81-90. PubMed ID: 19118035
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
[TBL] [Abstract][Full Text] [Related]
27. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
Porta C; Figlin RA
J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
[TBL] [Abstract][Full Text] [Related]
28. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
29. Tuftelin 1 (TUFT1) Promotes the Proliferation and Migration of Renal Cell Carcinoma
Lin H; Zeng W; Lei Y; Chen D; Nie Z
Pathol Oncol Res; 2021; 27():640936. PubMed ID: 34257606
[TBL] [Abstract][Full Text] [Related]
30. Ghrelin promotes renal cell carcinoma metastasis via Snail activation and is associated with poor prognosis.
Lin TC; Liu YP; Chan YC; Su CY; Lin YF; Hsu SL; Yang CS; Hsiao M
J Pathol; 2015 Sep; 237(1):50-61. PubMed ID: 25925728
[TBL] [Abstract][Full Text] [Related]
31. PI3K and AKT: Unfaithful Partners in Cancer.
Faes S; Dormond O
Int J Mol Sci; 2015 Sep; 16(9):21138-52. PubMed ID: 26404259
[TBL] [Abstract][Full Text] [Related]
32. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
[TBL] [Abstract][Full Text] [Related]
33. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
34. PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.
Badoiu SC; Greabu M; Miricescu D; Stanescu-Spinu II; Ilinca R; Balan DG; Balcangiu-Stroescu AE; Mihai DA; Vacaroiu IA; Stefani C; Jinga V
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176098
[TBL] [Abstract][Full Text] [Related]
35. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
36. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
37. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.
Son JY; Yoon S; Tae IH; Park YJ; De U; Jeon Y; Park YJ; Rhyu IJ; Lee BM; Chung KH; Lim JE; Lee SJ; Lee HW; Kwak JH; Kim HS; Choi HY
Cancer Med; 2018 Oct; 7(10):5083-5095. PubMed ID: 30160042
[TBL] [Abstract][Full Text] [Related]
38. Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway.
Hao J; Chen Q; Feng Y; Jiang Q; Sun H; Deng B; Huang X; Guan J; Chen Q; Liu X; Wang Y; Cao P; Feng F; Li X
Cell Death Dis; 2023 Apr; 14(4):247. PubMed ID: 37024452
[TBL] [Abstract][Full Text] [Related]
39. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
Papadimitrakopoulou V
J Thorac Oncol; 2012 Aug; 7(8):1315-26. PubMed ID: 22648207
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
